Bioage Labs Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bioage Labs Inc (BIOA)
Bioage Labs Inc stock price live, this page displays NASDAQ BIOA stock exchange data. View the BIOA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Bioage Labs Inc real time stock price chart below.
What Is the Bioage Labs Inc Stock Price Today?
The Bioage Labs Inc stock price today is 10.60.
What Is the Stock Symbol for Bioage Labs Inc?
The stock symbol for Bioage Labs Inc is "BIOA."
What Stock Exchange Does Bioage Labs Inc Trade On?
Bioage Labs Inc is listed and trades on the NASDAQ stock exchange.
Is Bioage Labs Inc a Good Stock to Buy?
Determining whether Bioage Labs Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BIOA quote. (ISIN: US09077V1008)
What Is the Bioage Labs Inc Stock Price Today?
The Bioage Labs Inc stock price today is 10.60.
What Is the Stock Symbol for Bioage Labs Inc?
The stock symbol for Bioage Labs Inc is "BIOA."
What Stock Exchange Does Bioage Labs Inc Trade On?
Bioage Labs Inc is listed and trades on the NASDAQ stock exchange.
Is Bioage Labs Inc a Good Stock to Buy?
Determining whether Bioage Labs Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BIOA quote. (ISIN: US09077V1008)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.10
10.63
52 wk Range
4.38
25.95
BIOA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.1010.63
52 wk Range
4.3825.95
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BIOA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
35.63
Upside
+236.08%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Why is BioAge Labs stock plunging 60% today?- Investing.com
- Bioage Labs Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Why is BioAge Labs stock plunging 60% today?
- Investing.com
- Why is BioAge Labs stock plunging today?
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 35.63
(+236.08% Upside)
Bioage Labs Inc Earnings Call Summary for Q4/2024
- BioArctic reports Q4 2024 net revenues of $101M, with royalty revenues up 38% to SEK 96.7M
- Company projects profitability in 2025 with pre-tax profit of SEK 1B and milestone payments of $130M expected
- Stock declined 1.36% in aftermarket trading, down 76% over the past year, trading at $4.42
- R&D expenses expected to rise 50-80% in 2025; company exploring new indications and expanding infusion capacity
- CEO Gunilla Oswald announces "BioArctic two point zero" era, emphasizing profitability and future growth
Last Updated: 2025-02-13, 04:38 a/m
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
-0.58 / --
Revenue / Forecast
2.45M / --
Compare BIOA to Peers and Sector
Metrics to compare | BIOA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.2x | −2.2x | −0.4x | |
PEG Ratio | −0.31 | −0.34 | 0.00 | |
Price/Book | 1.3x | 2.2x | 2.6x | |
Price / LTM Sales | 47.0x | 4.7x | 3.1x | |
Upside (Analyst Target) | 183.0% | 55.6% | 47.9% | |
Fair Value Upside | Unlock | −3.8% | 6.3% | Unlock |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Bioage Labs (BIOA) Stock Price Today?
The Bioage Labs stock price today is 10.60 USD.
What Stock Exchange Does Bioage Labs Trade On?
Bioage Labs is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Bioage Labs?
The stock symbol for Bioage Labs is "BIOA."
What Is the Bioage Labs Market Cap?
As of today, Bioage Labs market cap is 486.51M USD.
What Is Bioage Labs's Earnings Per Share (TTM)?
The Bioage Labs EPS (TTM) is -2.37.
When Is the Next Bioage Labs Earnings Date?
Bioage Labs will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is BIOA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Bioage Labs Stock Split?
Bioage Labs has split 0 times.
How Many Employees Does Bioage Labs Have?
Bioage Labs has 61 employees.
What is the current trading status of Bioage Labs (BIOA)?
As of Aug 17, 2026, Bioage Labs (BIOA) is trading at a price of 10.60 USD, with a previous close of 10.60 USD. The stock has fluctuated within a day range of 10.10 USD to 10.63 USD, while its 52-week range spans from 4.38 USD to 25.95 USD.
What Is Bioage Labs (BIOA) Price Target According to Analysts?
The average 12-month price target for Bioage Labs is 35.63 USD, with a high estimate of 73 USD and a low estimate of 20 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +236.08% Upside potential.
What Is the BIOA Premarket Price?
BIOA's last pre-market stock price is 10.31 USD. The pre-market share volume is 620.00, and the stock has decreased by -0.29, or -2.74%.
What Is the BIOA After Hours Price?
BIOA's last after hours stock price is 10.57 USD, the stock has decreased by -0.03, or -0.28%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.